financetom
Business
financetom
/
Business
/
Nazara Tech to scale-up marketing spends in Q2; expects subscriber additions
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nazara Tech to scale-up marketing spends in Q2; expects subscriber additions
Sep 15, 2021 6:03 AM

Nazara Technologies stock has seen a 30 percent upmove in the last six months and is up 85 percent from its issue price. In an interview with CNBC-TV18, Manish Agarwal, CEO of Nazara Technologies, discussed the outlook.

Share Market Live

NSE

“While Google problem is getting sorted, there are many such advertising networks, which we have explored and found that we could scale our marketing spends and net new subscriber additions keeping in mind similar kind of unit economics. Hence our marketing spends are not going to drop this quarter, they are going to be higher than the previous one, which means that our new subscribers will grow versus our previous quarter,” he said.

Also Read:

Factoring in 31% profit growth in Nifty50 in FY22; negative on media cos: Kotak Institutional Equities

With regard to slowdown in Kiddopia business in the US, he said, “Growth rate slowdown is directly marked to marketing spends. If your marketing spends are lower, your relative subscriber addition is lower and hence your growth rate would be lesser. As we figure out more and more opportunities to spend more Dollars on marketing, we would be able to get the growth back.”

From a market perspective, Agarwal said that Kiddopia has 4-5 percent market share.

Last year, the company grew roughly at around 80 percent. “Given the size of the market, given the retention engagement numbers that we have, we want to be super aggressive as the attribution problem gets solved,” he said.

For the full interview, watch the accompanying video.

Catch all live market action here.

(Edited by : Dipika Ghosh)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Clear Channel Q3 revenue beats estimates on strong ad demand
Clear Channel Q3 revenue beats estimates on strong ad demand
Nov 6, 2025
Overview * Clear Channel Q3 revenue up 8.1%, beating analyst expectations * Adjusted EBITDA for Q3 beats consensus, reflecting strong operational performance * Net loss for Q3 missed analyst estimates Outlook * Company expects Q4 2025 revenue between $441 mln and $456 mln * Clear Channel sees full-year 2025 revenue between $1.584 bln and $1.599 bln * Company projects full-year...
Quebecor Q3 revenue up 1.1%, net income rises 24.9%
Quebecor Q3 revenue up 1.1%, net income rises 24.9%
Nov 6, 2025
Overview * Quebecor Q3 2025 revenue grows 1.1%, adjusted EBITDA up 5.7% * Net income for Q3 2025 rises 24.9% yr/yr * Videotron announces C$800 mln Senior Notes offering due 2032 Result Drivers * TELECOMMUNICATIONS GROWTH - Increased adjusted EBITDA and revenues in the Telecommunications segment, driven by a rise in mobile telephony connections and Internet subscriptions * SERVICE EXPANSION...
Prestige Consumer Heathcare beats Q2 revenue expectations, tightens FY forecast 
Prestige Consumer Heathcare beats Q2 revenue expectations, tightens FY forecast 
Nov 6, 2025
Overview * Prestige Q2 revenue of $274.1 mln beats analyst expectations despite a 3.4% decline yr/yr * Adjusted EPS of $1.07 for Q2 beats analyst estimates * Company repurchased 1.1 mln shares in Q2, enhancing shareholder value Outlook * Prestige maintains fiscal 2026 revenue outlook at $1,100 mln to $1,115 mln * Company tightens fiscal 2026 adjusted EPS outlook to...
Esperion Q3 revenue up 69% on prescription volumes
Esperion Q3 revenue up 69% on prescription volumes
Nov 6, 2025
Overview * Esperion Q3 2025 total revenue grows 69% yr/yr to $87.3 mln * Net income for Q3 missed analyst expectations * Reached settlement with Dr. Reddy's to delay generics until 2040 Outlook * Esperion expects sustainable profitability beginning in Q1 2026 * Company reiterates 2025 operating expenses forecast of $215 mln to $235 mln * Esperion anticipates bempedoic acid...
Copyright 2023-2026 - www.financetom.com All Rights Reserved